Lam Carol J, Jacobson Daniel R, Rankin Matthew M, Cox Aaron R, Kushner Jake A
McNair Medical Institute, Pediatric Diabetes and Endocrinology, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas 77030.
Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.
J Clin Endocrinol Metab. 2017 Aug 1;102(8):2647-2659. doi: 10.1210/jc.2016-3806.
The cellular basis of persistent β-cell function in type 1 diabetes (T1D) remains enigmatic. No extensive quantitative β-cell studies of T1D pancreata have been performed to test for ongoing β-cell regeneration or neogenesis.
We sought to determine the mechanism of β-cell persistence in T1D pancreata.
We studied T1D (n = 47) and nondiabetic control (n = 59) pancreata over a wide range of ages from the Juvenile Diabetes Research Foundation Network of Pancreatic Organ Donors with Diabetes via high-throughput microscopy.
We quantified β-cell mass, β-cell turnover [via Ki-67 and terminal deoxynucleotide transferase-mediated dUTP nick end labeling (TUNEL)], islet ductal association, and insulin/glucagon coexpression in T1D and control pancreata.
Residual insulin-producing β cells were detected in some (but not all) T1D cases of varying disease duration. Several T1D pancreata had substantial numbers of β cells. Although β-cell proliferation was prominent early in life, it dramatically declined after infancy in both nondiabetic controls and T1D individuals. However, β-cell proliferation was equivalent in control and T1D pancreata. β-cell death (assessed by TUNEL) was extremely rare in control and T1D pancreata. Thus, β-cell turnover was not increased in T1D. Furthermore, we found no evidence of small islet/ductal neogenesis or α-cell to β-cell transdifferentiation in T1D pancreata, regardless of disease duration.
Longstanding β-cell function in patients with T1D appears to be largely a result of β cells that persist, without any evidence of attempted β-cell regeneration, small islet/ductal neogenesis, or transdifferentiation from other islet endocrine cell types.
1型糖尿病(T1D)中β细胞持续发挥功能的细胞基础仍不清楚。尚未对T1D胰腺进行广泛的定量β细胞研究以检测是否存在持续的β细胞再生或新生。
我们试图确定T1D胰腺中β细胞持续存在的机制。
我们通过高通量显微镜研究了青少年糖尿病研究基金会糖尿病胰腺器官捐赠者网络中不同年龄范围的T1D(n = 47)和非糖尿病对照(n = 59)胰腺。
我们对T1D和对照胰腺中的β细胞质量、β细胞更新[通过Ki-67和末端脱氧核苷酸转移酶介导的dUTP缺口末端标记(TUNEL)]、胰岛导管关联以及胰岛素/胰高血糖素共表达进行了定量。
在一些(但不是全部)病程不同的T1D病例中检测到了残留的产生胰岛素的β细胞。一些T1D胰腺中有大量的β细胞。虽然β细胞增殖在生命早期很突出,但在婴儿期后,非糖尿病对照和T1D个体中的β细胞增殖都显著下降。然而,对照和T1D胰腺中的β细胞增殖情况相当。在对照和T1D胰腺中,β细胞死亡(通过TUNEL评估)极为罕见。因此,T1D中β细胞更新没有增加。此外,无论病程长短,我们在T1D胰腺中均未发现小胰岛/导管新生或α细胞向β细胞转分化的证据。
T1D患者长期的β细胞功能似乎很大程度上是β细胞持续存在的结果,没有任何β细胞再生、小胰岛/导管新生或从其他胰岛内分泌细胞类型转分化的迹象。